 Phase IIA will evaluate the safety and efficacy of 3 randomized treatment groups in new onset T1DM patients to assess if the antisense DNA-treated co-stimulation-impaired immunoregulatory dendritic cells iDC will safely preserve andor increase B-cell mass resulting in improvement andor normalization of blood glucose levels and glycated hemoglobin A1c. 